Sana Biotechnology to Present at September 2023 Investor Conferences
2023年8月31日 - 5:05AM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
changing the possible for patients through engineered cells, today
announced that it will webcast its presentations at five
investor conferences in September. The presentations will feature a
business overview and update by Steve Harr, Sana’s President and
Chief Executive Officer, and Nate Hardy, Sana’s Chief Financial
Officer.
- Steve Harr will present at Citi’s 18th Annual BioPharma
Conference at 10:30 a.m. ET on Wednesday, September 6, 2023.
- Steve Harr will present at the 2023 Wells Fargo Healthcare
Conference at 2:15 p.m. ET on Thursday, September 7, 2023.
- Nate Hardy will present at the HC Wainwright 25th Annual Global
Investment Conference at 10:00 a.m. ET on Monday, September 11,
2023.
- Steve Harr will present at the Morgan Stanley 21st Annual
Healthcare Conference at 1:35 p.m. ET on Tuesday, September 12,
2023.
- Nate Hardy will present at the 2023 Cantor Global Healthcare
Conference at 10:55 a.m. ET on Wednesday, September 27, 2023.
The webcasts will be accessible on the Investor Relations page
of Sana’s website at https://sana.com/. A replay of each
presentation will be available at the same location for 30 days
following the corresponding conference.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are a passionate
group of people working together to create an enduring company that
changes how the world treats disease. Sana has operations in
Seattle, Cambridge, South San Francisco, and Rochester. For more
information about Sana Biotechnology, please visit
https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision; the Company’s
participation at Citi’s 18th Annual BioPharma Conference, the 2023
Wells Fargo Healthcare Conference, the HC Wainwright 25th Annual
Global Investment Conference, the Morgan Stanley 21st Annual
Healthcare Conference, and the 2023 Cantor Global Healthcare
Conference; and the subject matter of the Company’s presentations
at those conferences. All statements other than statements of
historical facts contained in this press release, including, among
others, statements regarding the Company’s strategy, expectations,
cash runway and future financial condition, future operations, and
prospects, are forward-looking statements. In some cases, you can
identify forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,”
“may,” “objective,” “plan,” “positioned,” “potential,” “predict,”
“seek,” “should,” “target,” “will,” “would” and other similar
expressions that are predictions of or indicate future events and
future trends, or the negative of these terms or other comparable
terminology. The Company has based these forward-looking statements
largely on its current expectations, estimates, forecasts and
projections about future events and financial trends that it
believes may affect its financial condition, results of operations,
business strategy and financial needs. In light of the significant
uncertainties in these forward-looking statements, you should not
rely upon forward-looking statements as predictions of future
events. These statements are subject to risks and uncertainties
that could cause the actual results to vary materially, including,
among others, the risks inherent in drug development such as those
associated with the initiation, cost, timing, progress and results
of the Company’s current and future research and development
programs, preclinical and clinical trials, as well as economic,
market and social disruptions, including due to the COVID-19 public
health crisis. For a detailed discussion of the risk factors that
could affect the Company’s actual results, please refer to the risk
factors identified in the Company’s SEC reports, including but not
limited to its Quarterly Report on Form 10-Q dated August 3, 2023.
Except as required by law, the Company undertakes no obligation to
update publicly any forward-looking statements for any reason.
Investor Relations & Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
過去 株価チャート
から 4 2024 まで 5 2024
Sana Biotechnology (NASDAQ:SANA)
過去 株価チャート
から 5 2023 まで 5 2024